Acetazolamide for Altitude Sickness

This trial aims to test whether the drug Acetazolamide can reduce symptoms of altitude sickness, which includes inflammation and other bodily stress when traveling to high altitudes. Researchers seek to understand how high altitudes affect the body and whether this drug can counteract those effects. Participants will take either Acetazolamide or a placebo (a pill with no active drug) to determine any differences in outcomes. The trial is suitable for healthy non-smokers with no history of altitude-related illnesses who haven't traveled above 8,000 feet in the past month. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

Yes, you will need to stop taking any anti-inflammatory medications, steroids, stimulants, or other agents that might affect breathing sensitivity, as these are not allowed during the trial.

Research has shown that acetazolamide is generally safe for preventing altitude sickness. One study found that taking 125 mg twice daily before climbing can help reduce symptoms. Another study demonstrated that it can lower the risk of sickness at high altitudes by 48% compared to a placebo.

Most treatments for altitude sickness, like dexamethasone or ibuprofen, work by reducing inflammation or pain. However, acetazolamide is unique because it targets the root cause of altitude sickness by enhancing the body’s ability to acclimate to high altitudes. It does this by promoting better breathing and improving the balance of fluids and electrolytes, helping prevent symptoms before they start. Researchers are excited about acetazolamide because it offers a proactive approach, potentially reducing the severity and onset of altitude sickness symptoms.

Studies have shown that acetazolamide effectively prevents acute mountain sickness (AMS) when taken before ascending to high altitudes. For example, one study found that taking 125 mg of acetazolamide twice daily significantly reduced the risk of AMS. Another study confirmed that this dose is more effective than lower doses for prevention. Acetazolamide accelerates the body's adjustment to high altitudes, alleviating symptoms like headaches and nausea. Specifically, 1 in 8 people who take it experience relief from AMS symptoms within 24 hours of reaching high altitude. Overall, research strongly supports using acetazolamide to prevent AMS. Participants in this trial will receive either acetazolamide or a placebo to evaluate its effectiveness in preventing AMS.¹⁶⁷⁸⁹